Yvonne Greenstreet Sells 8,924 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet sold 8,924 shares of the firm’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $4,034,094.20. Following the transaction, the chief executive officer owned 65,409 shares in the company, valued at $29,568,138.45. This trade represents a 12.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Yvonne Greenstreet also recently made the following trade(s):

• On Monday, August 18th, Yvonne Greenstreet sold 6,979 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $453.27, for a total value of $3,163,371.33.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $456.35 on Friday. The business’s fifty day moving average price is $441.57 and its 200 day moving average price is $338.75. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $484.21. The stock has a market capitalization of $59.82 billion, a PE ratio of -184.76 and a beta of 0.36. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm had revenue of $773.69 million for the quarter, compared to analysts’ expectations of $633.54 million. During the same period last year, the business posted ($0.13) earnings per share. The firm’s revenue for the quarter was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Wall Street Zen upgraded Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Oppenheimer raised Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 target price on the stock in a research report on Monday, August 4th. Truist Financial initiated coverage on Alnylam Pharmaceuticals in a research report on Monday, July 21st. They issued a “buy” rating and a $385.00 target price on the stock. Needham & Company LLC increased their target price on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Finally, Jefferies Financial Group increased their target price on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a “buy” rating in a research report on Monday, July 7th. Twenty-four analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $439.58.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Alnylam Pharmaceuticals by 1.8% during the second quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock worth $4,336,064,000 after acquiring an additional 240,534 shares during the period. T. Rowe Price Investment Management Inc. grew its holdings in Alnylam Pharmaceuticals by 0.8% during the first quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock worth $1,192,988,000 after acquiring an additional 33,696 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Alnylam Pharmaceuticals by 5.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock valued at $946,466,000 after purchasing an additional 185,783 shares during the period. Geode Capital Management LLC increased its stake in Alnylam Pharmaceuticals by 3.3% in the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock worth $779,857,000 after purchasing an additional 75,936 shares in the last quarter. Finally, Orbis Allan Gray Ltd increased its stake in Alnylam Pharmaceuticals by 29.8% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after purchasing an additional 486,489 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.